All together, these data indicated that CPFA treatment was able to remove the serum components capable to induce the rapid ERK1 and SMAD2/3 phosphorylation during endotoxemia, and that LBP may be considered a key factor not only in LPS/TLR4 signaling but also in the pro-fibrotic activity of TGF-β pathway. The gene discussed is MAPK3; the disease is serum lipopolysaccharide activity.